This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
A 12-week regimen of AbbVie's "3D" combo pill (the protease inhibitor ABT-450, NS5A inhibitor ombitasvir, and polymerase inhibitor dasabuvir) has also demonstrated high cure rates. In the PEARL-III trial, SVR rates reached 99% for previously untreated genotype 1 patients without liver cirrhosis. AbbVie expects approval by the end of 2014.
Similarly, a regimen of daclatasvir, asunaprevir, and the polymerase inhibitor BMS-791325 taken for 12 weeks cured 92% of previously untreated patients. Merck also has a promising combo in the works: the protease inhibitor MK-5172 and NS5A inhibitor MK-8742.
No comments:
Post a Comment